# 10x Genomics Inc. (TXG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Providers & Services. Price $62.65, market value $8.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). 10x Genomics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 4.00**. A PEG of 4.00 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 13.2×**. Each dollar of revenue is priced at 13.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 9.9×**. The shares trade at 9.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.5%** (5-yr avg 0.1%). Free cash flow equals 1.5% of the market value, above its five-year average of 0.1%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Gross margin: 70.0%**. 10x Genomics Inc. keeps 70.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -14.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -6.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -5.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -8.8%**. Return on all capital, debt included, is -8.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.2%**. Each dollar of assets produces -7.2% of profit.

## Growth
- **Revenue growth (1 yr): 5.2%** (3-yr 7.6%/yr, 5-yr 16.6%/yr). Revenue grew 5.2% over the last year, against 16.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 77.0%**. Earnings per share rose 77.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 4.46** (quick 4.46). Current assets cover the next year's liabilities 4.46 times.
- **Altman Z-score: 22.09**. A Z-score of 22.09 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. 10x Genomics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover 10x Genomics Inc.; the consensus is buy, with an average price target of $51.00 (-19% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 361.7%** (YTD 284.1%, 3-mo 101.8%). The shares are up 361.7% over twelve months including dividends.
- **From 52-week high: -6.4%** (461.4% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 2.29** (volatility 72%). Beta of 2.29 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TXG · Page: https://foliofundamentals.com/stocks/txg

Not investment advice.